Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Johnson & Johnson
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Prev close 266.94 · gapped below the open, then crossed back over prior close. High/low 267.34 at 4:15 am ET, 261.37 at 9:45 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of JNJ revenue | Skew |
|---|---|---|---|
| ANIKAnika Therapeutics, Inc. | 50.00% | 0.06% | 835× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In fiscal year 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8 %, 15.5 % and 11.1 % of the total gross revenues.”
$45.3B relationship
basisJNJ fy2025 · closed 2025-12 $94.2B
FILING10-K0000200406-26-000016cik 0000200406
“Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company ("JNJ"), under a license and collaboration agreement initially entered into in 2017.”
FILING10-K0001104659-26-019696cik 0001377121disclosed by PTGX
“In 2025, J&J MedTech accounted for 50% of our revenue.”
$56M relationship835× more of ANIK’s book than JNJ’s
basisANIK fy2025 · closed 2025-12 $113MJNJ fy2025 · closed 2025-12 $94.2B
FILING10-K
“In February 2023, we entered into the J&J License Agreement, pursuant to which we granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications in exchange for an upfront payment and the right to receive future milestone payments and royalties.”
FILING10-K0001628280-26-015165cik 0001855175disclosed by CTNM
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.”
FILING10-K0001408075-26-000009cik 0001408075disclosed by GPK
“MeiraGTx UK II Limited and Johnson & Johnson Innovative Medicine also entered into a Supply Agreement on the Closing Date pursuant to which MeiraGTx UK II Limited agreed to manufacture and supply the RPGR Product for Johnson & Johnson Innovative Medicine (the "Supply Agreement").”
FILING10-K0001104659-26-036494cik 0001735438disclosed by MGTX
“Pursuant to the J&J Collaboration Agreement, we received an upfront payment of $0.5 million from J&J for the information dissemination and data provision services under the agreement.”
FILING10-K0001628280-26-018261cik 0001739410disclosed by RLYB
“In November 2017, we entered into a collaboration and license agreement with J&J to research, develop and commercialize up to six bispecific antibodies generated through the use of our Azymetric and EFECT platforms, and in September 2025, we recognized a $25.0 million development milestone payment from J&J related to clinical progress of pasritamig entering into a Phase 3 trial in metastatic castration-resistant prostate cancer.”
FILING10-K0001937653-26-000015cik 0001937653disclosed by ZYME
“Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.”
FILING10-K0000200406-25-000038cik 0000200406
“Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products.”
FILING10-K0000200406-25-000038cik 0000200406
“In January 2025, we announced that we entered into a clinical trial and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with SC amivantamab for the first line treatment of patients with advanced NSCLC with EGFR exon 20 mutations, and we initiated a Phase 1b trial in the first quarter of 2025.”
FILING10-K0001193125-26-064005cik 0001796280disclosed by ORIC
“Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products.”
FILING10-K0000200406-25-000038cik 0000200406
“In July 2023, we entered into a global exclusive licensing, development, and commercialization agreement with Janssen”
FILING20-F0001760854-26-000003cik 0001760854disclosed by NBTX
“In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), part of a Johnson & Johnson company, to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other tauopathies.”
FILING20-F0001104659-26-027342cik 0001651625disclosed by ACIU
“The economic rights sold include (a) rights to a milestone payment of $20.0 million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine ("J&J") (the "AVTX-501 Milestone") and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited ("Apollo"), including up to $6.25 million of development milestones, up to $67.5 million in sales-based milestones, and royalty payments over a ten year period of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the "AVTX-007 Milestones and Royalties").”
FILING10-K0001534120-26-000011cik 0001534120disclosed by AVTX
“We have entered into a global partnership with Johnson & Johnson to provide our UNITY Fetal Antigen CTA (Clinical Trial Assay) in their AZALEA Phase 3 clinical trial of nipocalimab in pregnancies at risk for severe hemolytic disease of fetus and newborn (HDFN), and a related U.S.-specific partnership regarding development of a companion diagnostic product.”
FILING10-K0002070849-26-000017cik 0002070849disclosed by BLLN
“According to our collaboration and license agreement with Janssen, we have the right to elect to perform up to 50% of the overall commercialization effort in the United States (excluding any activities that Janssen has the exclusive right to perform). Janssen will commercialize cilta-cel in all countries excluding the United States and Greater China in accordance with a mutually agreed upon commercialization plan. If we launch cilta-cel in Greater China, we will lead commercialization efforts there and Janssen will have the right to elect to perform up to 30% of the overall commercialization effort there, excluding activities that we have the exclusive right to perform.”
FILING20-F0001801198-26-000008cik 0001801198disclosed by LEGN
“In July 2025, we entered into a co-promotion agreement with Johnson & Johnson MedTech, or J&J MedTech, (the "J&J Agreement"), to market and promote the use of ZILRETTA for OA knee pain in the U.S.”
FILING10-K0001628280-26-012297cik 0001396814disclosed by PCRX
“PONVORY ® tablets were approved in the U.S. for the treatment of RMS in adults in March 2021 and commercially launched in the U.S. by Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company in April 2021.”
FILING10-K0001628280-26-007460cik 0001347178disclosed by VNDA
“Janssen Pharmaceuticals Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals Inc.) On December 31, 2004, the Group entered into a research collaboration and license agreement with Janssen Pharmaceuticals Inc. (JPI).”
FILING20-F0001104659-26-062447cik 0001574232disclosed by ADXN
“The Company's marketing rights with respect to these products reverted to Johnson & Johnson on October 1, 2024, subsequent to which the Company stopped recognizing sales of these products.”
FILING10-K0000310158-26-000063cik 0000310158disclosed by MRK
“The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.”
FILING10-K0000200406-25-000038cik 0000200406
“The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.”
FILING10-K0000200406-25-000038cik 0000200406
“IMBRUVICA, which is developed in collaboration and co-commercialized in the U.S. with Pharmacyclics LLC, an AbbVie company.”
FILING10-K0000200406-26-000016cik 0000200406
Watchlist prices, news filtered to it, and its next report on your desk.
Johnson & Johnson has 19 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Johnson & Johnson’s own annual report or the counterparty’s, and carries the sentence that discloses it.
JNJ (Johnson & Johnson) has 19 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ADXN +4.91%, in the health bundle.